Navegar por autor "Jorge Fernández, Monica"

Mostrando ítems 1-13 de 13

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)

2011- Reboredo Lopez, Margarita; Candamio Folgar, Sonia; López López, Rafael; Quintero Aldana, Guillermo; Salgado Fernández, Mercedes; [et al.]
Bevacizumab plus capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients with metastatic colorectal cancer (mCRC) suitable for combination chemotherapy: Efficacy and safety findings from the phase II BECOX study (GEMCAD Study Gro

2013- Jorge Fernández, Monica
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

2015- Jorge Fernández, Monica
Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study.

2020- Vera, Ruth; Gómez, María Luisa; Ayuso, Juan Ramón; Figueras, Joan; García-Alfonso, Pilar; [et al.]
Dolor como factor predictor de depresion en el paciente oncologico: estudio de casos y controles. Estudio D-PRESS.

2013- Antolín Novoa, Silvia; Jorge Fernández, Monica; García. Gómez, Jesús
Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

2019- Martinez Lago, Nieves Purificacion; Carmona Campos, Marta; Gonzalez Villarroel, P; Salgado Fernández, Mercedes; De La Cámara Gómez, Juan Cruz; [et al.]
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; Covela Rúa, Marta; De La Cámara Gómez, Juan Cruz; González Villaroel, Paula; [et al.]
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

2014- Jorge Fernández, Monica
NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma-R0 resection, pCR, and toxicity analysis

2013- Jorge Fernández, Monica
Observational transversal study to relate functional status and age with the doublet or triplet chemotherapy based on capecitabine in advanced gastric cancer patients

2011- Jorge Fernández, Monica
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

2015- Gallardo Martín , Maria Elena; Fernández Montes, Ana; Varela Ferreiro, Silvia; Campos Balea, Begoña; Álvarez Gómez, Elena; [et al.]
Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

2019- Rivera, F.; Romero, C.; Jimenez-Fonseca, P.; Izquierdo-Manuel, M.; Salud, A.; [et al.]
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status

2014- Jorge Fernández, Monica